APA (7th ed.) Citation

A, G., M, L., A, B., R, V. T., A, A., A, T., . . . D, T. (2026). Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trial. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 58(7), 966. https://doi.org/10.1016/j.dld.2026.04.009

Chicago Style (17th ed.) Citation

A, Grancher, et al. "Sotorasib Plus Panitumumab and 5-fluorouracil in First-line Treatment of Patients with Unresectable KRAS G12C Mutated Colorectal Cancer Unfit for a Doublet/triplet Chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO Trial." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 58, no. 7 (2026): 966. https://doi.org/10.1016/j.dld.2026.04.009.

MLA (9th ed.) Citation

A, Grancher, et al. "Sotorasib Plus Panitumumab and 5-fluorouracil in First-line Treatment of Patients with Unresectable KRAS G12C Mutated Colorectal Cancer Unfit for a Doublet/triplet Chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO Trial." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 58, no. 7, 2026, p. 966, https://doi.org/10.1016/j.dld.2026.04.009.